Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies or compositions comprising the antibodies can be used to treat disease in which ADCC activity provides a benefit. In one embodiment, therefore, the antibodies or compositions comprising the antibodies can be used to treat cancer, lymphoproliferative disease or autoimmune disease.
1 . A composition comprising milk-derived antibodies, wherein the milk-derived antibodies have enhanced antibody-dependent cellular cytotoxicity (ADCC) activity.
2 - 28 . (canceled)
29 . A method of treating a subject, comprising:
administering to a subject in need thereof the composition of claim 1 in an amount effective to enhance ADCC in the subject.
30 . A method of treating a subject, comprising:
administering to a subject with a disease the composition of claim 1 in an amount effective to treat the disease.
31 - 39 . (canceled)
40 . A method for enhancing the ADCC activity of an antibody or antibodies, comprising:
modifying the glycosylation of the antibody or antibodies, wherein the glycosylation is modified by producing the antibody or antibodies in mammalian mammary epithelial cells.
41 - 53 . (canceled)
54 . A method, comprising:
(a) collecting the antibody from the milk of a transgenic non-human mammal engineered to express the antibody in its milk; and
(b) determining the ADCC activity of the antibody.
55 - 56 . (canceled)
57 . A method for producing an antibody, comprising:
(a) collecting the antibody from mammary epithelial cells engineered to express the antibody; and
(b) determining the ADCC activity of the antibody.
58 . (canceled)
59 . A composition comprising mammary epthelial cell-derived antibodies, wherein the antibodies have enhanced antibody-dependent cellular cytotoxicity (ADCC) activity.
60 - 97 . (canceled)